Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Part of paid clinical trials in Greenville, North Carolina.

Sponsor
Nuvig Therapeutics, Inc.
Study ID
NCT07095127
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Immune Thrombocytopenia (ITP)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • NVG-2089 — DRUG
    Study Treatment

Study Details

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

Key Dates

Start date
Sep 30, 2025
Status verified
May 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NVG-2089
    NVG-2089

Primary Outcome Measure

Evaluate incidence, nature and severity of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: From enrollment to end of treatment Week 20 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
East Carolina UniversityGreenvilleNorth Carolina27834
Sue Ann Joyner Joyner
[email protected]
252-744-9010

Find similar trials in Greenville, NC

By research site
East Carolina University· Greenville, NC

Related Studies